Navigation Links
Watson Announces Novel Oral Contraceptive Approval
Date:12/22/2010

MORRISTOWN, N.J., Dec. 22, 2010 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals (NYSE: WPI) today announced the U.S. Food and Drug Administration (FDA) approval of a novel oral contraceptive product – the first and only low dose oral contraceptive to combine 0.8 mg norethindrone and 0.025 mg ethinyl estradiol in chewable form, with four 75 mg ferrous fumarate (iron) placebo tablets. Taken orally, once daily, the product is proven effective in lowering the risk of pregnancy.

Watson's new oral contraceptive is a novel alternative to currently available birth control pills.  This pill's unique dosing combination and proven 24-day, active hormone regimen is intended to provide users with a low level of breakthrough bleeding and short, light, predictable periods.

"The approval of this oral contraceptive further strengthens Watson's robust and expanding branded Women's Health portfolio," said Fred Wilkinson, Executive Vice President, Global Brands. "We believe this product is an important addition to the oral contraceptive category, and that its characteristics will make it a desirable choice for women."

The novel contraceptive product, licensed from a subsidiary of Warner Chilcott plc, will be actively marketed to physicians by Watson's Global Brands division beginning in the second quarter 2011.

Recent partnerships with Gedeon Richter, HRA Pharma, Itero Biopharmaceuticals, the Population Council and Columbia Laboratories have enabled Watson to expand its branded offerings and pipeline in women's health to include therapies for infertility, prevention of pre-term birth, uterine fibroids, emergency contraception and long-term contraception.

The approval of the oral contraceptive is based on data from a 12-month, Phase 3, multicenter, open-label study that evaluated the safety and efficacy of the product for pregnancy prevention.  A
'/>"/>

SOURCE Watson Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Watson and Richter Announce Exclusive License Agreement for Esmya™
2. Watson Confirms Exalgo™ Patent Challenge
3. Watson Announces Pricing of Secondary Offering By Selling Stockholder
4. Watson Announces Commencement of Secondary Offering by Selling Stockholder
5. Watson To Present At The 2010 Credit Suisse Healthcare Conference
6. Watson Confirms Crestor® Patent Challenge
7. Watsons Generic Version of Lotrel ® Receives FDA Approval
8. Watson to Host Conference Call and Webcast to Discuss Third Quarter 2010 Earnings
9. Watson Reaches Settlement with Endo Over Opana® ER
10. Watson Confirms Azilect® Patent Challenge
11. Watson to Present at the Jefferies 2010 Global SpecPharma & European Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)...  Cohen, Placitella & Roth, PC is investigating ... Nymox Pharmaceutical Corporation ("Nymox" or "Company") (NASDAQ: ... 31, 2011 through November 2, 2014 ("Class Period").  ... its officers and directors publically disseminated materially false ... and 20(a) of the Securities Exchange Act of ...
(Date:11/26/2014)... VIEJO, Calif. , Nov. 26, 2014 /PRNewswire/ ... announced that the U.S. Food and Drug Administration ... its New Drug Application (NDA) for AVP-825. AVP-825 ... low-dose sumatriptan powder delivered intranasally utilizing a novel ... the Complete Response letter, and consistent with the ...
(Date:11/26/2014)...  BioScrip ® , Inc. (NASDAQ: BIOS ) announced ... Officer, will present at the Bank of America Merrill Lynch 2014 ... Date: , , , Wednesday, December 3, 2014 , , ... , , , Location: , , , Boca Raton Resort and ... BioScrip, Inc. is a leading national provider ...
Breaking Medicine Technology:Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4
... Craneware, Inc., the market leader in automated revenue ... with Kingman Regional Medical Center, a 235-bed non-profit ... of the nation,s five star hospitals in community ... InSight Denials® to the range of Craneware Revenue ...
... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), ... of products for central nervous system disorders, today announced ... will deliver a corporate presentation on Thursday, June 9, ... will take place as part of the Jefferies 2011 ...
Cached Medicine Technology:Kingman Adds Craneware Revenue Integrity Solution - InSight Denials® 2Kingman Adds Craneware Revenue Integrity Solution - InSight Denials® 3Kingman Adds Craneware Revenue Integrity Solution - InSight Denials® 4
(Date:11/28/2014)... (PRWEB) November 28, 2014 Before that Thanksgiving ... already preparing for the Christmas shopping season. Today, people will ... on Black Friday, the biggest retail shopping day of the ... or electronic device, New Albany dentist Dr. Ronald ... can improve oral health and literally brighten a few smiles. ...
(Date:11/28/2014)... November 28, 2014 talklocal ( ... to the right service professionals by phone in about 90 ... at least two tornadoes were reported to have touched down ... damage was reported following the tornadoes, Denver residents now know ... unexpected. Having TalkLocal is like having local pros in over ...
(Date:11/28/2014)... 28, 2014 Based in Minneapolis, MN, ... on delivering exemplary solutions to the income and asset ... In an effort to extend its reach across the ... protection, Secura Consultants has brought aboard financial service industry ... am a big believer in specialization. When I decided ...
(Date:11/28/2014)... This report presents a comprehensive investigation ... definite portrayal of the North American commercial center. ... variables driving the development of the business coupled ... of the business. , Complete report available ... the report "Worldwide Dental Report: 2014 Edition", low ...
(Date:11/28/2014)... CA (PRWEB) November 28, 2014 Top10inaction.com, ... officially announced the Best Styling Tools For Hair in ... hair styling tools, such as T3 Featherweight 2 Hair ... Dryer 2000, were listed. , With the significant increase ... devices become popular, but also home-used hair styling tools ...
Breaking Medicine News(10 mins):Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 2Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 3Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 4Health News:TalkLocal Launches In Denver A Week After Multiple Tornadoes Hit Near City 2Health News:Matt Lee, CLU, ChFC Joins Secura Consultants as New Brokerage Consultant 2Health News:Global Dental Market Report 2014 Edition Now Available at MarketReportsOnline.com 2Health News:Global Dental Market Report 2014 Edition Now Available at MarketReportsOnline.com 3Health News:T3 Featherweight 2 Hair Dryer Is Named As Best Hair Styling Tool 2
... Md., Dec. 7, 2011 A research team led by scientists ... this week showing how a bacterium, Helicobacter pylori , that ... been implicated in stomach cancer has managed for eons to turn ... it can thrive. Writing in a Journal of Biological ...
... recognize the following scenario: Their favorite player scores a three-point ... ball. But does the fact that he scored the last ... it change the probability that he will score again? ... Neiman at the Hebrew University in Jerusalem shatters the myth ...
... TUESDAY, Dec. 6 (HealthDay News) -- A woman,s risk of ... or is obese after age 60, a new study indicates. ... risk, but "the diabetes link had not been clearly shown," ... Lund University in Lund, Sweden. He is scheduled to ...
... symptoms following birth also reported intimate partner violence finds a ... International Journal of Obstetrics and Gynaecology . The study ... symptoms first reported this at six months after birth or ... abuse) in the perinatal period is associated with a range ...
... - Accelerated partial breast irradiation (APBI) brachytherapy, the ... as a treatment choice for women with early-stage ... later mastectomy, increased radiation-related toxicities and post-operative complications, ... to researchers from The University of Texas MD ...
... Supercomputer simulations at the Department of Energy,s Oak Ridge ... key class of proteins involved in drug detoxification. ... affiliated with ORNL and the University of Tennessee, have ... in a class of enzymes called P450s. Certain types ...
Cached Medicine News:Health News:Closing in on an ulcer- and cancer-causing bacterium 2Health News:Closing in on an ulcer- and cancer-causing bacterium 3Health News:Heads up Kobe Bryant! Research shows that trying for another 3-pointer is a mistake 2Health News:Diabetes, Obesity After 60 May Drive Up Breast Cancer Risk 2Health News:Depressive symptoms and intimate partner violence in the 12 months after childbirth 2Health News:Study finds side effects, complications, mastectomy more likely after partial breast irradiation 2Health News:Study finds side effects, complications, mastectomy more likely after partial breast irradiation 3Health News:Supercomputer reveals new details behind drug-processing protein model 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: